Provepharm continues its international expansion by signing three new distribution agreements in Europe
Provepharm announced that it has extended its international distribution network by signing new agreements covering eight additional European countries.
Provepharm has recently concluded one licensing and distribution agreement with NordMedica for the distribution of its product in the five Scandinavian countries – Norway, Sweden, Finland, Denmark and Iceland - and has also signed agreements with A VIPharma in Greece and Cyprus, and with Fresenius Kabi Portugal for the Portuguese market. As the product is already commercialized in France, the United Kingdom and Ireland, these new agreements mean that it will now be available to one-third of Europeans (more than 175 million people).
Following the centralized European regulatory marketing approval granted for its drug, these agreements represent another important milestone in the development of Provepharm’s distribution network in Europe.
In order to anticipate the rolling-out of this strategy to other regions of the world and its extension to new therapeutic applications, Provepharm has also strengthened its management in France by hiring five new executives. Three have been recruited by the R&D department as project managers in the areas of regulatory affairs, chemistry and galenical formulation, while another has joined the marketing department as project manager. A new director of supply chain post has also been created to ensure full control over the procurement of active substances and finished products supplied by CMOs.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
